Multidisciplinary Association for Psychedelic Studies

Multidisciplinary Association for Psychedelic Studies
Name	Multidisciplinary Association for Psychedelic Studies
Formation	1986
Founders	Ralph Metzner; Rick Doblin
Type	501(c)(3) nonprofit
Headquarters	Santa Cruz, California
Leader title	Founder and Executive Director
Leader name	Rick Doblin
Mission	Research and education on psychedelic substances

Multidisciplinary Association for Psychedelic Studies is a nonprofit research organization founded in 1986 that sponsors scientific studies of psychedelic substances, conducts clinical trials, and engages in public education. It operates at the intersection of biomedical research, regulatory affairs, and public policy, coordinating collaborations among academic institutions, pharmaceutical companies, and advocacy groups. Its activities have influenced regulatory decisions, academic discourse, and cultural conversations around substances such as psilocybin, MDMA, and LSD.

History

The organization was founded in 1986 by Rick Doblin and others including Ralph Metzner during a period influenced by the legacy of Timothy Leary, the emergence of the AIDS epidemic, and shifts following the enactment of the Controlled Substances Act. Early activities involved archival preservation of materials linked to Stanislav Grof, Alexander Shulgin, and the Harvard Psilocybin Project while simultaneously petitioning regulatory agencies such as the Food and Drug Administration and engaging with researchers at institutions like Johns Hopkins University, Imperial College London, and Yale University. Over subsequent decades the organization navigated legal controversies arising from cases like Operation Julie-era enforcement narratives and adapted to evolving frameworks such as breakthrough therapy designations pioneered during the 21st century.

Mission and Organization

The stated mission centers on funding and facilitating research on psychedelic-assisted therapies, harm reduction, and education. Its governance structure includes a board featuring figures from academia and philanthropy who have ties to institutions like Harvard University, Columbia University, and University of California, San Francisco. Programmatic leadership coordinates with regulatory bodies including the Drug Enforcement Administration and the National Institutes of Health while engaging bioethicists from centers such as The Hastings Center and research ethics committees at universities like Stanford University.

Research Programs and Clinical Trials

Research programs have targeted substances and modalities including MDMA-assisted psychotherapy, psilocybin-assisted therapy, and explorations into ketamine analogs. Clinical trials have been conducted in collaboration with academic centers such as Johns Hopkins University, Imperial College London, New York University, and Yale School of Medicine; studies addressed conditions like post-traumatic stress disorder, major depressive disorder, and substance use disorder. Trials seeking regulatory approval have followed pathways involving the Food and Drug Administration's breakthrough therapy designation mechanism and coordinated with institutional review boards at Massachusetts General Hospital and Mount Sinai Health System. Investigations have included neuroimaging collaborations with laboratories at MIT, University College London, and McGill University.

Funding and Partnerships

Funding streams have included private philanthropy from donors associated with foundations such as the Bezos Family Foundation-adjacent philanthropies, grants from institutional partners, and fundraising campaigns engaging networks in cities like San Francisco and Los Angeles. Strategic partnerships have been forged with biotech firms, academic research centers, and international collaborators including teams at University of Zurich, Karolinska Institutet, and Tel Aviv University. The organization has also interacted with policy-oriented entities like Open Society Foundations-affiliated projects and lobbied through coalitions that include members of the Drug Policy Alliance.

Advocacy, Education, and Public Outreach

Educational initiatives have included conferences featuring speakers from Johns Hopkins University, Imperial College London, Oxford University, and community trainings aimed at clinicians from institutions such as Massachusetts General Hospital. Advocacy efforts engaged legislative arenas in municipalities like Denver, Oakland, California, and Oregon and intersected with ballot campaigns influenced by movements linked to Decriminalize Nature and policy shifts following local initiatives. Public outreach involved collaborations with media outlets, documentary filmmakers connected to festivals like Sundance Film Festival, and academic publishing with partners at presses associated with Cambridge University Press and Oxford University Press.

Controversies and Criticism

Critiques have come from scholars and advocates associated with Harvard University, Columbia University, and community organizations who question commercialization strategies, conflicts of interest tied to biotech partnerships, and the pace of clinical translation. Ethical concerns raised by commentators at The Hastings Center and investigative reporting by outlets linked to journalism schools such as Columbia Journalism School addressed trial transparency, participant selection, and data sharing practices. Regulatory tensions with agencies like the Drug Enforcement Administration and debates within policymaking bodies in jurisdictions such as California and Oregon have added to contested public narratives.

Impact and Legacy

The organization has contributed to a renaissance in psychedelic research, catalyzing clinical programs at Johns Hopkins University, Imperial College London, Yale University, and multiple hospital systems including Massachusetts General Hospital and Mount Sinai Health System. Its role in advancing protocols for MDMA and psilocybin has influenced regulatory pathways at the Food and Drug Administration and inspired international research networks spanning Europe, Israel, and Canada with groups at University of Toronto and McGill University. The legacy includes training clinicians, shaping public policy debates in municipalities like Denver and Oregon, and seeding commercial and philanthropic ecosystems that connect to venture firms and research consortia in hubs such as San Francisco and Boston.

Category:Psychedelic research organizations